Helmedix

Developing novel therapies for autoimmune and inflammatory diseases such as rheumatoid arthritis, colitis, psoriasis and multiple sclerosis.

Launch date

2012

Employees

Market cap

Enterprise valuation

Melbourne Victoria (HQ)

Date	Investors	Amount	Round
Feb 2013	Brandon Capital Partners	AUD1.3m	Seed
Total Funding		CAD1.1m

Tech stackLearn more about the technologies and tools that this company uses.

By Country

By Industry

By Round

Recent News about Helmedix